Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study

Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, V.N. Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, View ORCID ProfileRaches Ella, William Blackwelder, Sai Prasad, Krishna Ella
doi: https://doi.org/10.1101/2021.12.28.21268468
Krishna Mohan Vadrevu
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddharth Reddy
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harsh Jogdand
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brunda Ganneru
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nizam Mirza
2Pranaam Hospital, Hyderabad, Telangana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V.N. Tripathy
3Prakhar Hospital, Kanpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandramani Singh
4All India Institute of Medical Sciences, Patna, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasant Khalatkar
5Meditrina Institute of Medical Sciences, Nagpur, Maharashtra, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddaiah Prasanth
6Cheluvamba Hospital, Mysore, Karnataka, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Rai
7All India Institute of Medical Sciences, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raches Ella
8Independent Consultant, Cambridge, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raches Ella
  • For correspondence: rachesella@gmail.com
William Blackwelder
9WB Statistical Consulting LLC, Bethesda, Maryland, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Prasad
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Ella
1Bharat Biotech, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background We assessed the safety, reactogenicity, and immunogenicity of BBV152 in an open-label age de-escalation study in three age cohorts of children from 18 years of age down to 2 years of age.

Methods This was a phase 2/3 open-label, multi-centre study done across six hospitals in India. All children received two 0.5mL doses of BBV152 (Covaxin®, Bharat Biotech International Ltd., Hyderabad, India), which is the same formulation indicated in adults. Participants were monitored for adverse events, and post-vaccination blood draws were collected to assess neutralising antibodies. A total of 526 children were enrolled into Group 1 (ages 12 through 18 years, n=176), Group 2 (ages 6 through 12 years, n=175), Group 3 (ages 2 through 6 years, n=175).

Findings There were no serious adverse events, deaths, or withdrawals due to an adverse event during the study. Vaccination with BBV152 was generally well tolerated, with no substantial difference in reactogenicity profiles between the different age groups. Similar immune responses were measured as microneutralisation (MNT) antibody titers in all three age groups. Vaccine-induced MNT responses in all groups were comparable to BEI reference sera run in the same assay. Seroconversion (measured by Plaque Reduction Neutralization Test (PRNT)) achieved high levels (95-98%) in all three groups four weeks after the second vaccination. The PRNT GMT ratio was 1·76 (95%CI: 1.32 – 2.33) (GMT all children subgroup / GMT in adults) had a lower limit ≥ 1, indicating superior antibodies in children when compared to adults. Vaccine responses were skewed towards a Th1 response with IgG1/IgG4 ratios above 1.

Interpretation BBV152 is well tolerated and immunogenic in children from 18 years down to 2 years of age. Immunogenicity analysis (by PRNT) shows superior antibody responses were observed in children compared to adults, suggesting that BBV152 will also be efficacious in this age group.

Competing Interest Statement

This work was funded by Bharat Biotech International Limited. KMV, SR, BR and SP, are employees of Bharat Biotech, with no stock options or incentives. Co-author, KE, is the Chairman and Managing Director of Bharat Biotech and owns equity in the company. RE and WB are independent clinical development and statistical consultants, respectively. NM, VNT, CS, VK, SP, NP, SRa, were principal investigators representing the study sites.

Clinical Trial

Registered with the Clinical Trials Registry (India) No. CTRI/2021/05/033752

Funding Statement

The sponsor of the study had no role in data collection, data analysis, data interpretation, or writing the report. A contract research organisation (CRO) was responsible for data analysis and generating the report. The unblinded CRO and several authors from Bharat Biotech had full access to the data in the study. Authors from Bharat Biotech had final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

1. Institutional Ethics Committee: ECR/1460/Inst/TG/2020 of Pranaam Hospital gave ethical approval for this work 2. Institutional Ethics Committee: ECR/1387/Inst/BR/2020 of All India Institute of Medical Sciences gave ethical approval for this work 3. Institutional Ethics Committee: ECR/134/Inst/KA/2013/RR-19 of Cheluvambha Hospital gave ethical approval for this work 4. Institutional Ethics Committee: ECR/608/Inst/MH/2014/RR-20 of Meditrina Institute of Medical Sciences gave ethical approval for this work. 5. Institutional Ethics Committee: ECR/1017/Inst/UP/2017/RR-21 of Prakhar Hospital gave ethical approval for this work. 6. Institutional Ethics Committee: ECR/538/Inst/DL/2014/RR-20 of All India Institute of Medical Sciences gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This study was funded by Bharat Biotech International Limited. Registered with the Clinical Trials Registry (India) No. CTRI/2021/05/033752

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study
Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, V.N. Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, Raches Ella, William Blackwelder, Sai Prasad, Krishna Ella
medRxiv 2021.12.28.21268468; doi: https://doi.org/10.1101/2021.12.28.21268468
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study
Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, V.N. Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, Raches Ella, William Blackwelder, Sai Prasad, Krishna Ella
medRxiv 2021.12.28.21268468; doi: https://doi.org/10.1101/2021.12.28.21268468

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (940)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)